Triamcinolone acetonide is under clinical development by Bausch & Lomb and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Triamcinolone acetonide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Triamcinolone acetonide overview
Triamcinolone acetonide (Xipere) is a corticosteroid, acts as immunosuppressive and anti-inflammatory agent. It is formulated as suspension for suprachoroidal route of administration and is being developed based on Suprachoroidal space platform technology. Xipere is indicated for the treatment of macular edema associated with uveitis.
Triamcinolone acetonide (CLS1001) is under development for the treatment of Uveitic Macular Edema, diabetic macualr edema and macular edema associated with non-infectious uveitis. The drug is administered as a suprachoroidal injectable suspension and acts by targeting the glucocorticoid receptors. It was also under development for sympathetic ophthalmia, temporal arteritis, ocular inflammatory conditions, branch retinal vein occlusion and central retinal vein occlusion, non-infectious intermediate, posterior and pan-uveitis.
Bausch & Lomb overview
Bausch & Lomb, a subsidiary of Bausch Health Companies Inc, is a vision-care company with focus on the protection, enhancement and restoration of eyesight. It provides over-the-counter supplements, eye care products, contact lenses, ophthalmic pharmaceuticals, lens care products, ophthalmic surgical devices and instruments. The company develops, manufactures and markets eye health products for the treatment of a wide range of eye conditions such as conjunctivitis, glaucoma, eye allergies, dry eye and retinal diseases. It has presence across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Bausch & Lomb is headquartered in Bridgewater, New Jersey, the US.
For a complete picture of Triamcinolone acetonide’s drug-specific PTSR and LoA scores, buy the report here.